Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 12/20 | 0.48 |
| ▸ | ERBB2 | P04626 | 4/20 | 0.48 |
| ▸ | SRC | P12931 | 5/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.43 |
| ▸ | CSF1R | P07333 | 3/20 | 0.39 |
| ▸ | KDR | P35968 | 2/20 | 0.38 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.36 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.36 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.36 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.36 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.36 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.36 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5475801 | 0.89 | EGFR (0.54) | EGFRERBB2SRCKCNH2CSF1R | |
| SCHEMBL4033919 | 0.82 | EGFR (0.45) | EGFRERBB2SRCKCNH2CSF1R | |
| Hydrochloric Acid SCHEMBL5664057 | 0.81 | EGFR (0.44) | EGFRERBB2SRCKCNH2CSF1R | |
| SCHEMBL6403835 | 0.78 | SRC (0.54) | EGFRERBB2SRCCSF1RKDR | |
| Hydrochloric Acid SCHEMBL4034029 | 0.75 | EGFR (0.70) | EGFRERBB2SRCKCNH2KDR | |
| SCHEMBL4029452 | 0.74 | EGFR (0.60) | EGFRERBB2SRCKCNH2KDR | |
| SCHEMBL6621804 | 0.74 | ERBB2 (0.41) | EGFRERBB2SRCKCNH2KDR | |
| SCHEMBL6312780 | 0.72 | SRC (0.43) | EGFRERBB2SRCCSF1RKDR | |
| SCHEMBL6620697 | 0.71 | SLC6A2 (0.42) | EGFRERBB2SRCKCNH2KDR | |
| SCHEMBL6619064 | 0.69 | EGFR (0.45) | EGFRERBB2SRCKCNH2KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050043336-A1 | Quinazoline derivatives as antitumor agents | ASTRAZENECA AB (SE) | 2005-02-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050043336-A1 | Quinazoline derivatives as antitumor agents | ERBB2, ERBB3, ABL1 | EGFR 4/4885ERBB2 1/4885SRC 111/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.